Diversity in Reporting Signals of Inflammatory CNS Adverse Events Linked to ICIs

Background

Inflammatory CNS irAEs, although uncommon, can lead to severe clinical outcomes and pose challenges in diagnosis and management. Understanding the immune microenvironments of primary CNS tumors and brain metastases is crucial, as these differences may influence the incidence and severity of irAEs.

Data Highlights

Key Findings

• Inflammatory CNS irAE reporting signals showed tumor phenotype-associated heterogeneity.
• Adjusted odds ratios indicated stronger signals for brain metastases compared to primary CNS tumors.
• Stricter noninfectious phenotype definitions yielded more specific reporting signals than broader neuroinflammatory definitions.
• Single-cell analyses localized strict inflammatory module activity primarily to myeloid and T/NK compartments.
• Spatial transcriptomics provided secondary descriptive visualization without demonstrating irAE-onset tissue states.

Clinical Implications

The findings suggest that clinicians should consider tumor phenotype when evaluating the risk of inflammatory CNS irAEs in patients receiving ICIs. Enhanced awareness of these differences may aid in the early recognition and management of potential adverse events.

Conclusion

The study highlights the importance of understanding tumor-specific immune microenvironments in the context of ICI-related CNS toxicity. These findings serve as a basis for further investigation into the mechanisms underlying these adverse events.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities
2. Acta Neuropathologica, 2023 -- Immune Profiling in Glioblastoma Reveals an Inflammatory Perivascular Subtype Linked to Improved Survival Outcomes
3. The ASCO Post, 2021 -- Study Identifies Gut Microbes Associated With Combination Immunotherapy Response and Adverse Events
4. NCCN Guidelines® Insights, 2024 -- Management of Immunotherapy-Related Toxicities, Version 2.2024
5. Central nervous system adverse events of immune checkpoint inhibitors, 2024
6. Frontiers in Immunology — Investigate the heterogeneity of colorectal cancer patients at the single-cell level prior to and subsequent to immunotherapy
7. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024 - PubMed
8. Central nervous system adverse events of immune checkpoint inhibitors - PubMed
9. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) - PMC